首页> 美国卫生研究院文献>Therapeutics and Clinical Risk Management >Update on Diagnosis and Treatment of Adult Pulmonary Alveolar Proteinosis
【2h】

Update on Diagnosis and Treatment of Adult Pulmonary Alveolar Proteinosis

机译:诊断和治疗成人肺肺泡蛋白病的更新

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary surfactant homeostasis disorder resulting in buildup of lipo-proteinaceous material within the alveoli. PAP is classified as primary (autoimmune and hereditary), secondary, congenital and unclassifiable type based on the underlying pathogenesis. PAP has an insidious onset and can, in some cases, progress to severe respiratory failure. Diagnosis is often secured with bronchoalveolar lavage in the setting of classic imaging findings. Recent insights into genetic alterations and autoimmune mechanisms have provided newer diagnostics and treatment options. In this review, we discuss the etiopathogenesis, diagnosis and treatment options available and emerging for PAP.
机译:肺肺泡蛋白症(PAP)是一种罕见的肺表面活性剂稳态紊乱,导致肺泡内的脂蛋白质材料的累积。基于潜在的发病机制,PAP被归类为主要(自身免疫和遗传性),二次,先天性和无分配的类型。 PAP有一个阴险的发病,可以在某些情况下进展严重呼吸衰竭。在经典成像结果的设置中,诊断通常用支气管肺泡灌洗。最近对遗传改变和自身免疫机制的见解提供了更新的诊断和治疗方案。在本综述中,我们讨论了可用的病因发生,诊断和治疗方案,并为PAP进行了新兴。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号